ES2152207T3 - Derivados condensados de la purina. - Google Patents

Derivados condensados de la purina.

Info

Publication number
ES2152207T3
ES2152207T3 ES90120056T ES90120056T ES2152207T3 ES 2152207 T3 ES2152207 T3 ES 2152207T3 ES 90120056 T ES90120056 T ES 90120056T ES 90120056 T ES90120056 T ES 90120056T ES 2152207 T3 ES2152207 T3 ES 2152207T3
Authority
ES
Spain
Prior art keywords
lower rent
represents hydrogen
purina
aliciclic
rental
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90120056T
Other languages
English (en)
Inventor
Fumio Suzuki
Junichi Shimada
Takeshi Kuroda
Kazuhiro Kubo
Akira Karasawa
Tetsuji Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Application granted granted Critical
Publication of ES2152207T3 publication Critical patent/ES2152207T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Abstract

SE DESCUBREN DERIVADOS DE PURINA CONDENSADOS REPRESENTADOS POR LA FORMULA: EN DONDE REPRESENTA O EN LA CUAL R3 REPRESENTA HIDROGENO, ALQUILO INFERIOR, O BENCILO; REPRESENTANDO CADA UNO DE LOS X1 Y X2, INDEPENDIENTEMENTE, HIDROGENO, ALQUILO INFERIOR, ARALQUILO O FENILO; Y N ES UN ENTERO DE 0 O 1; R1 REPRESENTA HIDROGENO, ALQUILO INFERIOR, ALQUILO ALICICLICO, NORADAMANTAN-3-ILO, DICICLOPROPILOMETILO O ESTIRILO; Y R2 REPRESENTA HIDROGENO, ALQUILO INFERIOR O ALQUILO ALICICLICO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ELLOS. LOS DERIVADOS Y LAS SALES FARMACEUTICAMENTE ACEPTABLES SE USAN COMO DIURETICOS, AGENTES DE PROTECCION RENAL, AGENTES ANTI-ALERGICOS E HIPOTENSIVOS.
ES90120056T 1989-10-20 1990-10-19 Derivados condensados de la purina. Expired - Lifetime ES2152207T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27340389 1989-10-20

Publications (1)

Publication Number Publication Date
ES2152207T3 true ES2152207T3 (es) 2001-02-01

Family

ID=17527409

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90120056T Expired - Lifetime ES2152207T3 (es) 1989-10-20 1990-10-19 Derivados condensados de la purina.

Country Status (7)

Country Link
US (1) US5270316A (es)
EP (1) EP0423805B1 (es)
JP (1) JP2988711B2 (es)
AT (1) ATE195739T1 (es)
CA (1) CA2028235C (es)
DE (1) DE69033614T2 (es)
ES (1) ES2152207T3 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
DE69130869T2 (de) * 1990-10-18 1999-06-10 Kyowa Hakko Kogyo Kk Xanthinderivate
US5756735A (en) * 1990-10-18 1998-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5442062A (en) * 1991-10-24 1995-08-15 The Upjohn Company Imidazole derivatives and pharmaceutical compositions containing the same
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
JPH08507068A (ja) * 1993-02-26 1996-07-30 シェリング・コーポレーション ２−ベンジル−多環式グアニン誘導体およびそれらの製造方法
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
EP0814809B1 (en) 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
US6294541B1 (en) 1996-06-06 2001-09-25 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
WO1998015555A1 (fr) * 1996-10-07 1998-04-16 Kyowa Hakko Kogyo Co., Ltd. Derives de purine fondue
AU1722999A (en) 1997-12-12 1999-07-05 Euro-Celtique S.A. Preparation of 3-substituted adenines and imidazo pyridines
AU4396899A (en) * 1998-07-02 2000-01-24 Kyowa Hakko Kogyo Co. Ltd. Remedies for diabetes
US6319928B1 (en) * 1998-11-30 2001-11-20 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase IV inhibition activity
AU4053800A (en) 1999-04-02 2000-10-23 Euro-Celtique S.A. Purine derivatives having phosphodiesterase iv inhibition activity
MEP42208A (en) * 1999-11-12 2011-02-10 Biogen Idec Inc Polycycloalkylpurines as adenosine receptor antagonists
WO2001034604A2 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Adenosine receptor antagonists and methods of making and using the same
CA2395414A1 (en) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd Condensed purine derivative
AU2001230913B2 (en) * 2000-01-14 2005-06-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
AU2002219977B2 (en) 2000-12-01 2008-01-24 Biogen Idec Ma Inc. Condensed purine derivatives as A1 adenosine receptor antagonists
US6423844B1 (en) 2001-06-06 2002-07-23 The United States Of America As Represented By The Secretary Of The Navy Process for making 1,2,4-triazolo[4,3-a][1,3,5]triazine-3,5,7-triamine
AU2004234245A1 (en) * 2003-04-25 2004-11-11 Kyowa Hakko Kogyo Co., Ltd. Fused pyrimidine derivative
US20070093534A1 (en) * 2003-05-06 2007-04-26 Aldo Ammendola Modulation of Pathogenicity
WO2009152133A1 (en) 2008-06-10 2009-12-17 Abbott Laboratories Novel tricyclic compounds
AR079234A1 (es) 2009-12-01 2012-01-04 Abbott Lab Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar afecciones oncologicas, del sistema nervioso y/o del sistema inmune.
NZ599938A (en) 2009-12-01 2014-08-29 Abbvie Inc Novel tricyclic compounds
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
WO2016042775A1 (en) * 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN114106000B (zh) * 2021-12-15 2023-11-24 中国科学院新疆理化技术研究所 一种咪唑并[4,5-d]嘧啶酮三环类衍生物及抗肿瘤用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE863525A (fr) * 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
SE7810946L (sv) 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4870181A (en) 1985-02-04 1989-09-26 A. H. Robins Company, Incorporated Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2])octan-3-yl)aminobenzamides
US4710503A (en) 1985-02-07 1987-12-01 Euroceltique S.A. 6-thioxanthine derivatives
US5086176A (en) * 1989-03-29 1992-02-04 Merrell Dow Pharmaceuticals Inc. Tricyclic fused adenine derivatives
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
AU623755B2 (en) * 1989-03-29 1992-05-21 Merrell Pharmaceuticals Inc. Selective adenosine receptor compounds
JP2980658B2 (ja) * 1989-09-14 1999-11-22 協和醗酵工業株式会社 ｓ―トリアゾロ〔３，４―ｉ〕プリン誘導体

Also Published As

Publication number Publication date
EP0423805B1 (en) 2000-08-23
CA2028235C (en) 1997-01-21
DE69033614T2 (de) 2001-04-19
US5270316A (en) 1993-12-14
CA2028235A1 (en) 1991-04-21
JPH03204880A (ja) 1991-09-06
EP0423805A3 (en) 1992-01-02
EP0423805A2 (en) 1991-04-24
ATE195739T1 (de) 2000-09-15
JP2988711B2 (ja) 1999-12-13
DE69033614D1 (de) 2000-09-28

Similar Documents

Publication Publication Date Title
ES2152207T3 (es) Derivados condensados de la purina.
DK104792A (da) 8-chlor-1,5-benzothiazepinderivater og fremgangsmaade til fremstilling deraf
ATE51231T1 (de) Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als antiallergische mittel.
ES8701727A1 (es) Un procedimiento para la preparacion de un derivado de dihi-dropiridina
ATE21894T1 (de) Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln.
DE69027562D1 (de) Xanthinverbindungen
DE59711733D1 (de) 3-thiocarbamoylpyrazol-derivate als pestiziden
ES2192081T3 (es) Derivados de purina antivirales.
DK0386675T3 (da) Xanthinderivater
ES2159758T3 (es) Nuevas n-aminoalquilfluorenocarboxamidas; una nueva clase de ligandos especificos a subtipos del receptor de la dopamina.
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
ES2009785B3 (es) Procedimiento para preparar derivados de tioxantona.
ATE165601T1 (de) Benzopyran-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als zellenschutzmittel
DE69433161D1 (de) O6-substituierte guaninederivate, verfahren zu ihre herstellung und ihre anwendung für behandlung von tumorzellen
DE3879653D1 (de) Virusinhibierende heterocyclische verbindungen.
ES2152379T3 (es) Dihidropiridinas condensadas y su utilizacion para la produccion de preparados farmaceuticos.
NO943111L (no) Diacylsubstituerte guanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende disse
ZA852561B (en) Tetrahydrothienopyridines,a process for their preparation and their use as medicaments
ES2032838T3 (es) Un procedimiento para preparar derivados tetrahidropirido (1,2-a)indol.
DE3779190D1 (de) T-butyl ergolinderivate.
DK0619817T3 (da) Hidtil ukendte farmaceutisk aktive flaviliumforbindelser
CS902588A2 (en) Method of 2-aminotetrahydroisoquinoline derivatives production
ES2192794T3 (es) Colorantes disazoicos reactivos.
ES2157542T3 (es) Nuevos derivados de elipticina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
RU94017645A (ru) Производные хиназолина и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 423805

Country of ref document: ES